Search This Blog

Wednesday, June 24, 2026

Absci prices $100 m underwritten common at $7.41 per share to fund advancement of ABS-201

 

Absci prices $100 million underwritten common stock offering at $7.41 per share to fund advancement of ABS-201

  • Eli Lilly and leading institutional investors are participating in the underwritten common stock offering.
  • Proceeds will also be used for general corporate purposes.
  • Absci reports positive interim Phase 1 data from HEADLINE trial of ABS-201.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)